Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02027961 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
A Phase 1 study of Melanoma, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 11
- Study locations
NCT02027961 is a Phase 1 study of Melanoma that has completed, run by MedImmune. The registered enrollment target is 68 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT02027961, a Phase 1 study of Melanoma, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with metastatic or unresectable melanoma with BRAF-mutation positive or wild-type (WT) BRAF, respectively.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- DRUG Trametinib
- DRUG Dabrafenib
Study Locations (11)
California
- Research Site - Los Angeles
- Research Site - San Francisco
Other
- Research Site - Villejuif
- Research Site - Naples
Arizona
- Research Site - Scottsdale
Florida
- Research Site - Miami Beach
Illinois
- Research Site - Chicago
Massachusetts
- Research Site - Boston
Missouri
- Research Site - St Louis
Ontario
- Research Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2013-12-20 |
| Est. Completion | 2018-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02027961
The ClinicalTrials.gov registry entry for NCT02027961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT02027961 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Other, Arizona.
Frequently Asked Questions
What is clinical trial NCT02027961 about?
NCT02027961 is a clinical study titled "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone". The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with metastatic or unresectable melanoma with BRAF-mutation positive or wild-type (...
What is the current status of trial NCT02027961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2013-12-20. Estimated completion is 2018-04-24.
What conditions does trial NCT02027961 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02027961?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Trametinib (DRUG), Dabrafenib (DRUG).
Who is sponsoring clinical trial NCT02027961?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02027961 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.